PepGen Inc.
NASDAQ:PEPGBiotechnology
+$0.09 today
- Market cap
- $265.27M
- Beta
- 1.93
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.12
Volume 3.39M
Average 1.37M
PEPG Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
PepGen Inc.NASDAQ: PEPG
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $1.19M rose 6.7% year over year, ahead of the -37.0% change in trailing-twelve-month other income / expenses. Sequentially, it fell 15.6% from the prior quarter. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +6.7% holds above the trailing-twelve-month pace of -37.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 4.01M USD
- Year-over-year change
- -43.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.01M | -43.9% |
| FY2024 | 2024-12-31 | 7.14M | +14.9% |
| FY2023 | 2023-12-31 | 6.21M | +114.0% |
| FY2022 | 2022-12-31 | 2.9M | +1787.8% |
| FY2021 | 2021-12-31 | (172K) | — |
Other Income / Expenses vs competitors
How PEPG compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -37.0% is the 4th highest of 8, against a peer median of -38.1%.
- Over three fiscal years its annual growth of +11.3% compares with a peer median of +6.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.38M USD | -21.0% | +49.6% | — | |
| LTM Mar 2026 | $11.31M USD | -50.1% | -26.8% | 61.4% | |
| LTM Mar 2026 | $9.52M USD | -61.3% | -24.7% | 150.7% | |
| LTM Mar 2026 | $5.31M USD | -38.1% | — | — | |
| LTM Mar 2026 | $4.08M USD | -37.0% | +11.3% | — | |
| LTM Mar 2026 | $2.67M USD | -17.9% | +37.4% | 507.8% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$2.61M USD | +55.1% | — | — |
| LTM Mar 2026 | -CHF 6.37M CHF | -427.8% | — | — | |
| Peer median (excluding PEPG) | — | -38.1% | +6.4% | 150.7% | |
Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.18M | 1.51M | 1.4M |
| Gross Profit | 0 | 0 | (1.18M) | (1.51M) | (1.4M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.8M | 54.08M | 68.13M | 76.48M | 71.04M |
| Selling, General & Admin | 8.11M | 14.22M | 16.64M | 21.26M | 22.57M |
| Operating Expenses | 27.11M | 68.3M | 83.58M | 96.23M | 92.22M |
| Depreciation & Amortization | 178K | 493K | 1.18M | 1.51M | 1.4M |
| EBITDA | (27.1M) | (64.91M) | (77.37M) | (89.09M) | (88.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (27.11M) | (68.3M) | (84.77M) | (97.74M) | (93.61M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 2.79M | 6.4M | 7.14M | 4.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (172K) | 2.9M | 6.21M | 7.14M | 4.01M |
| Income Before Tax | (27.28M) | (65.4M) | (78.55M) | (90.6M) | (89.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 3.71M | 73K | (617K) | 49K |
| Net Income | (27.28M) | (69.1M) | (78.63M) | (89.98M) | (89.66M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.22) | (4.42) | (3.30) | (2.85) | (2.12) |
| EPS (Diluted) | (1.22) | (4.42) | (3.30) | (2.85) | (2.12) |
| Weighted Avg Shares | 22.39M | 15.64M | 23.8M | 31.58M | 42.22M |
| Weighted Avg Shares (Diluted) | 22.39M | 15.64M | 23.8M | 31.58M | 42.22M |
PepGen Inc.
NASDAQ:PEPG
Intrinsic Alpha fair value
Locked
Current Price
$3.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.